Hanan Mohamed Nomeir

Dr. Hanan Mohamed Nomeir

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 February 2023 in Epilepsy Research
Verified
Journal Article
Closed access
ANAzhar Mohamed Nomair
Azhar Mohamed Nomair
JMJaidaa Farouk Mekky
Jaidaa Farouk Mekky
SEShaymaa Ali El-Hamshary
Shaymaa Ali El-Hamshary
HNHanan Mohamed Nomeir
Hanan Mohamed Nomeir

5 February 2024 in Clinical Rheumatology
Verified
Journal Article
Open access
PDF file
ANAzhar Mohamed Nomair
Azhar Mohamed Nomair
AAAbeer Abdelati
Abeer Abdelati
FDFatma I. Dwedar
Fatma I. Dwedar
RERehab Elnemr
Rehab Elnemr
YKYasmine N. Kamel
Yasmine N. Kamel
HNHanan Mohamed Nomeir
Hanan Mohamed Nomeir
Background: There are currently no validated criteria that entirely explain or predict response to methotrexate (MTX) treatment in rheumatoid arthritis (RA). We tried to identify the connection between three variants (RFC1 G80A (rs1051266), TYMS 2R/3R (rs34743033), and ATIC C347G (rs2372536)) in the folate pathway of MTX metabolism and the response to MTX monotherapy in a cohort of RA cases. Methods: A prospective study on 100 RA patients on MTX monotherapy was performed. Disease activity was measured at the start of treatment and 6 months after treatment with MTX. The patients were then split into two groups: those who responded to the treatment and those who did not. The molecular genetic study for the RFC1 (G80A) variant was employed via the PCR-restriction fragment length polymorphism (PCR–RFLP) technique, the ATIC (C347G) variant was performed using TaqMan allelic discrimination real-time PCR, and the tandem repeat sequences of TYMS (2R/3R) were amplified by conventional PCR and detected by agarose gel electrophoresis. Results: The genotype distribution of RFC-1 (G80A) showed significant variations among non-responders and responders in the recessive genetic model. A significant difference was found in TYMS (2R/3R) in the dominant and heterozygous genetic models. However, ATIC (C347G) genotype frequency did not exhibit substantial link with drug response in all genetic models. Furthermore, the genotype and allele rates of the analyzed variants did not show any significant association with adverse events in all genetic models. Conclusion: The 80AA genotype of RFC-1 G80A and the 2R/3R or 3R/3R genotypes of TYMS 2R/3R are more vulnerable to the good consequences of MTX therapy. Key Points • Current recommendations support the gold standard role of MTX as a first-line monotherapy for RA patients. However, up to 40% of RA patients do not respond or exhibit partial response to MTX.• Persistent disease activity due to treatment unresponsiveness will affect the long-term outcomes in RA patients.• We aimed, through molecular genetic study, to identify the connection between three variants in the folate pathway of MTX metabolism and the response to methotrexate monotherapy in a cohort of RA patients.

1 October 2013 in Egyptian Journal of Medical Human Genetics
Verified
Journal Article
Open access
DMDalia A. Maharem
Dalia A. Maharem
SGSalwa H. Gomaa
Salwa H. Gomaa
MGMarwa K. El Ghandor
Marwa K. El Ghandor
EMEhab Mohamed
Ehab Mohamed
KMKhaled A. Matrawy
Khaled A. Matrawy
HNHanan Mohamed Nomeir
Hanan Mohamed Nomeir
Disorders of bone and mineral metabolism contribute to an increased prevalence of vascular calcification (VC) with its adverse clinical outcomes in patients with chronic kidney disease (CKD). The pathogenesis of VC is not fully understood. Fetuin-A is one of the inhibitors of calcification whose level is lowered in patients with CKD. In addition fetuin-A 256Ser/Ser (allele G) might affect serum fetuin-A levels. The aim of this work was to study the association between fetuin-A and its gene and VC and also with bone mineral density (BMD) in patients with CKD on conservative treatment, on maintenance of hemodialysis (HD) and those who underwent renal transplantation.This study included twenty eight CKD patients on HD, seventeen CKD patients on conservative treatment and twelve patients who underwent transplantation in addition to sixteen healthy controls. All were subjected to history taking, clinical examination, laboratory investigations including fasting serum glucose, urea, creatinine, albumin, lipid profile, C-reactive protein (CRP), estimated glomerular filteration rate (e-GFR), calcium, phosphorus, calcium by phosphorus product (Ca×PO4), intact parathyroid hormone (iPTH), alkaline phosphatase (Alk), fetuin-A and genotyping for the common functional polymorphisms on fetuin-A (Thr256Ser) using the Polymerase chain reaction (PCR) technique. Radiological examination included ultrasonography of carotid arteries and assessment of VC by plain X-ray and assessment of BMD.Serum calcium was lower, phosphorus, Ca×PO4, iPTH and Alk were higher in all patient groups than control. Fetuin-A was lower in all patient groups compared to controls. VC was detected in 39.2% HD patients, 29.4% patients on conservative treatment and 25% patients on transplantation. T-score of BMD was significantly lower in all patient groups than control. There was no statistically significant difference between patients and control groups according to the frequencies of the three fetuin-A genotypes (C→G) but the distribution of the fetuin-A (C→G); Thr256Ser gene polymorphisms in the studied subjects showed significant correlation with low serum fetuin-A levels. VC was associated with older age, male gender, longer HD duration, lower albumin, higher LDL-c, higher carotid plaques and lower T-score value of BMD.VC was evident in patients with CKD and it is related to atherosclerosis and lower BMD. Fetuin-A was lower in all patients with CKD with significant relation between serum fetuin-A level and its gene polymorphism but not with VC

26 August 2021 in Italian Journal of Pediatrics
Verified
Journal Article
Open access
PDF file
AIAhlam M. Ismail
Ahlam M. Ismail
AHAliaa Monir Higazi
Aliaa Monir Higazi
HNHanan Mohamed Nomeir
Hanan Mohamed Nomeir
NFNAGLAA MAKRAM FARAG
NAGLAA MAKRAM FARAG
Background: Immune thrombocytopenic purpura (ITP) is an acquired complex autoimmune thrombocytopenia. Uncontrolled cellular immune response is one of the key triggers for the loss of immune tolerance in ITP patients. The purpose of this study was to investigate the association of IL-23/Th17, IL-17A and IL-17A rs2275913 gene polymorphism with ITP in Egyptian children. Methods: 60 patients with ITP and 50 healthy control children from Minia city- Egypt were involved. Serum levels of IL-23 and IL-17A were determined by enzyme-linked immunosorbent assay. The frequency of Th17 cells was measured using flow cytometer. Genotyping for IL-17A was performed via polymerase chain reaction-restriction fragment length polymorphism. Results: Comparing children with ITP to controls, serum levels of IL-23 and IL-17A as well as Th17 cells percentage were significantly increased (p < 0.001). Also, higher levels of these ILs and Th17 cells percentage were associated with decreased platelet count within ITP patients (p < 0.001). Analysis of genotype frequencies for IL-17A rs2275913 polymorphism and its alleles (A, G) showed no significant difference between cases and controls. Likewise, no significant differences were demonstrated between acute and chronic ITP regarding both IL-17A rs2275913 polymorphism prevalence and levels of IL-23, IL-17A plus Th17 cells percentage. The frequency of A alleles was 85 and 86% within patients and controls, respectively. Conclusions: Elevated levels of IL-23, IL-17A and Th17 cells may be involved in ITP pathogenesis while IL-17A polymorphism rs2275913 is not prevalent in Egyptian children with ITP.

19 December 2022 in Vaccines
Verified
Journal Article
Open access
PDF file
MSManal Mohamed Saber
Manal Mohamed Saber
ANAzhar Mohamed Nomair
Azhar Mohamed Nomair
AOAshraf M. Osman
Ashraf M. Osman
HNHanan Mohamed Nomeir
Hanan Mohamed Nomeir
NFNAGLAA MAKRAM FARAG
NAGLAA MAKRAM FARAG
Data for predicting the severity and mortality of coronavirus disease 2019 (COVID-19) are limited, and investigations are ongoing. Endothelial monocyte-activating protein II (EMAP-II) is a multifunctional polypeptide with pro-inflammatory properties. EMAP-II is a significant pathogenic component in chronic inflammatory lung diseases and lung injury. In this study, we aimed to assess the potential utility of EMAP-II as a predictor of COVID-19 severity and mortality. This study included 20 healthy volunteers and 60 verified COVID-19 patients. Nasopharyngeal samples from COVID-19-positive subjects and normal volunteers were collected at admission. The nasopharyngeal samples were subjected to EMAP-II real-time polymerase chain reaction (RT-PCR). EMAP-II RNA was not detected in nasopharyngeal swabs of normal controls and mild to asymptomatic COVID-19 patients and was only detectable in severe COVID-19 patients. EMAP-II critical threshold (Ct) was positively associated with lymphocyte percentages and oxygen saturation (p < 0.001) while being negatively associated with age (p = 0.041), serum CRP, ferritin, and D-dimer levels (p < 0.001). EMAP-II Ct cutoff ≤34 predicted a worse outcome in COVID-19 illness, with a sensitivity and specificity of 100%. Our study suggests that EMAP-II could be considered a potential biomarker of COVID-19 severity. EMAP-II can predict the fatal outcome in COVID-19 patients.

29 January 2022 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Closed access
RERania K. Eid
Rania K. Eid
MAMona F. Arafa
Mona F. Arafa
DADalia S. Ashour
Dalia S. Ashour
EEEbtessam Essa
Ebtessam Essa
HZHager S. Zoghroban
Hager S. Zoghroban
GMGamal M. El Maghraby
Gamal M. El Maghraby